FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...